BioDelivery Sciences misses top endpoint in Ph3 for pain drug; InSite reveals upbeat mid-stage data on anti-pain treatment;

> BioDelivery Sciences International ($BDSI), which uses drug-delivery technologies in its development of new treatments, said it did not meet the primary endpoint of its late-stage study of BEMA Buprenorphine for moderate to severe chronic pain. Release

> The Medicines Company ($MDCO) said that it has commercially released a 12-hour version of the blood-pressure drug clevidipine for injection. The FDA approved the formulation in June. Item

> InSite Vision ($INSV) reported upbeat data from a mid-stage study of its BromSite treatment, which uses its DuraSite delivery technology, for the treatment of pain and inflammation from ocular surgery. Announcement

> India's Sparsha Pharma International, a maker of fentanyl patches, said it has begun to commercialize to next-gen transdermal patches for use in treating pain. Item

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.